How to Answer the Question — Are Drugs Real Threats to Biological Systems or Overrated Innocuous Chemicals? by Nunes, Bruno
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






How to Answer the Question — Are Drugs Real Threats
to Biological Systems or Overrated Innocuous
Chemicals?
Bruno Nunes
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/59886
1. Introduction
Recent years have brought a new awareness about the potential deleterious environmental
impacts of a multiplicity of anthropogenic substances. We have now reached a scientific/
technological standpoint that allows the prediction of most likely effects posed by large groups
of substances, including pharmaceutical drugs, and their effects on exposed biota. However,
as is the case of pharmaceutical drugs, scarce are the studies and unequivocal data that
establish a direct linkage between their environmental presence and dispersal, and toxicity in
exposed organisms. Several drawbacks are systematically invoked by detractors of the issue
of pharmaceutical contamination when considering this issue, from the unmistakable low
levels in which drug residues are found, to the absence of effects caused by metabolites being
excreted from biologic systems. However, one cannot discard the evidences: drug residues are
present in most environmental matrices, including the particular case of the aquatic compart‐
ment; the number of drugs, their metabolites and degradation products detected in these
environmental matrices is alarmingly high, and never stopped increasing since their first
detections; some of these drugs are not characterized in terms of toxicity towards the majority
of exposed organisms, and their toxic outcomes are unpredictable; the use, release and
presence of these substances will not end, or be decreased in a near future, a factor that should,
at least, work as an additional stimulus for the development of research into this field.
Therapeutic agents, both human and veterinary, are modern commodities that make part of
the developed society. These chemicals are usually developed to fulfil a series of criteria,
mainly effectiveness, safety, comfort of use, therapeutic success, and low incidence of side
effects. However, the issue of environmental fate of these molecules has only recently been
raised, and the main approach established in international guidelines (e.g. European Medi‐
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cines Agency, EMA) takes only in consideration the expected levels in which these compounds
may occur in the aquatic compartment. Thus, a consensual precautionary principle was
adopted, considering only the levels of dispersion, based on estimates of consumption, that
drugs may undergone. No specific guidelines or testing protocols were ever developed to
analyse the biological effects of pharmaceuticals in the environment, and efforts devoted so
far to this problematic have always relied on the quest, validation and proposal of more
accurate and reliable analytical methodologies. However, rather than quantifying the presence
or levels of drugs in the environment, an integrative approach that characterizes their toxic
effects on multiple components of the ecosystem is now much required. Only with results from
a comprehensive, well-suited battery of multi-species biotests, complemented by a systematic
survey of published data, it will be possible to answer to the big question: are drugs in the
environment real threats to biological systems, or overrated innocuous chemicals?
The main drawback of studying the potential deleterious effects of drugs in the environment
is the type of compound that one might expect to find. Considering that a rough estimate of
the number of distinct substances presently in use in Europe is around 3000, it is possible to
sustain the complexity of this task. Taking into consideration that a considerable number of
these substances share a similar pharmacology/toxicology, we can reduce this number surely
to a certain hundreds; however, being metabolised and excreted, the formation of metabolites
and degradation products will increase again the number of substances that one can find in
the wild. An additional factor to consider is the absence of toxicity data for the majority of
metabolites and degradation products. For all the given reasons, the ecotoxicological profile
of most therapeutic drugs is largely unknown, and a large effort must be devoted to the
proposal, validation and use of a comprehensive set of biomarker tools. This effort will be
mandatory to diagnose exposure to pharmaceuticals for a vast number of species, and to
predict the magnitude of the threat posed by pharmaceutical compounds to non-target
organisms.
Even if this approach is satisfactorily followed, the discrepancy of experimental data can be
another factor to consider. For some drugs, a considerable amount of scientific data is now
available, which should facilitate the interpretation of their ecotoxicological profiles and risks.
However, this is not always a simple and immediate task to perform. In fact, for some drugs,
the already compiled information is sparse, contradictory and based on erroneous assump‐
tions, making extremely difficult the interpretation of data. This is the case of paracetamol, as
shown by Nunes et al. [1]. According to this study, the toxicity of paracetamol is highly
variable, even among species of the same phylogeny; however, this situation is even more
complicated if one considers the variations of magnitude in responses obtained with standar‐
dized bioassays.
More than being an exhaustive attempt to establish a comprehensive review of what has been
done in recent years regarding the diagnostic of effects of drugs in the wild, the present chapter
intends to summarize the new evidences showing that therapeutic drugs and their residues/
metabolites can indeed work as environmental pollutants, and may constitute additional
sources of chemical stress to already polluted areas. It is also our intention to show the linkage
between exposures to low, almost vestigial, levels of pollutants, and the most significant
biological deleterious effects, in several biological models, mainly from the aquatic environ‐
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ment. Both field and laboratory studies will serve as case studies of particular importance to
demonstrate that pharmaceuticals, despite their almost negligible concentrations, can be of
environmental concern for sensitive key elements of the ecosystem. On the other hand, one of
the main purposes of this review is the establishment of key guidelines, for the development,
implementation and validation of toxicological biomarker tools to assess the subtle effects
elicited by pharmaceuticals.
The issue of pharmaceuticals as contaminants has been a hot topic in environmental sciences
for more than two decades [2]. However, this is not a novel issue, and early studies conducted
during the mid 70s already showed the presence of significant amounts of clofibric acid (the
pharmacologically active metabolite of several fibrates that explains their activity as lipid
lowering agents), in water from the sewage systems of a North American town, Kansas City
[3]. This same compound was again found in water quality monitoring studies, initially aimed
to quantify pesticide residues, in Germany [4], almost twenty years after their initial detection.
This apparent coincidence meant that compounds such as clofibric acid might have a general
and ubiquitous presence, being highly dispersed among water compartments [5]. This was
then confirmed by subsequent studies, showing that the dispersion of these pharmaceutical
substances was not limited in any way to sewage or even freshwater, since it could also be
detected in the North Sea. Clofibric acid has an undisputable historical importance, that was
not followed by the confirmation of its (eco)toxicogical significance [7, 8]; nevertheless, and
from a merely retrospective analysis, its detection in several water samples was a major event
that served as basis for a new area of environmental toxicology, devoted to the study of the
presence and effects of therapeutic drugs in the environment.
Given the enormous body of evidence that was compiled since the mid 90s to the present day,
from studies involving all possible aquatic matrices (freshwater, sea water, sewage effluents,
drinking water, groundwater) it is almost impossible not to consider the issue of drugs and
their ecotoxicological effects one of the most challenging scenarios for years to come. Conse‐
quently, the presence of pharmaceutical residues in the wild is nowadays a matter of interest,
among the scientific community and the general public [1, 9, 10, 11]. This interest derives from
the intrinsic features that these compound possess. Pharmaceuticals are biologically active,
capable of exerting effects in a large number of organisms, even when in extremely low
concentrations. Drugs are widely used and dispersed, being ubiquitously found in the aquatic
environment, as a result of the overall low degradation efficiency of sewage treatment plants;
drugs are present in surface water, groundwater, and even oceans; furthermore, these
substances are refractory to biological degradation or can assume other forms after metabolism
[2, 9, 12], largely toxicologically uncharacterised especially for wild organisms. An adequate
lipophylicity allows drugs to be slightly water soluble, but readily absorbed by living organ‐
isms [8, 13]. Aquatic organisms are by far more exposed to pharmaceutical residues. The
deleterious impact of specific therapeutic compounds on aquatic organisms has already been
shown to occur, even under real scenarios of contamination [13, 14, 15].
Drugs reach the aquatic compartment mainly via sewage systems. The use of pharmaceutical
drugs requires its ultimate elimination from the patients’ organisms, which results in its
presence in the sewage treatment system, when it is present [2]. In modern western societies,
sewage treatment plants (STPs) are common and generally efficient. However, the purpose of
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conventional STPs is reducing the amount of organic pollution, and not the elimination of
often-recalcitrant compounds such as drugs. This results frequently in extremely low removal
rates in STPs when it concerns to pharmaceuticals [16], requiring the implementation of novel
and usually expensive technologies. This results in the continuous release of drugs an their
metabolites into the receiving waters. Given that the amount introduced into the wild generally
equals the sum of drug that is naturally degraded by natural pathways, it is possible to sustain
that pharmaceuticals are environmentally pseudopersistent [17, 18]. Other alternative routes
can also explain the presence of pharmaceuticals in the aquatic compartment, but in a lesser
extent, such as release from manufacturing industries, and leachates from landfills [19].
Despite the existence of distinct routes by which pharmaceutical substances reach water
bodies, it is important to stress that the majority of the residues result from human use and
release, and from the inefficacy of treatments systems. Consequently, the issue of aquatic
contamination by drugs is intrinsically connected to the personal use made by human
consumers, which cannot be stopped or prevented, even if more advanced solutions to mitigate
the presence of drugs are developed and implemented.
As a consequence of human use, several classes of drugs are routinely detected and quantified
in the most varied water matrices. The most prominent classes of drugs found in the wild
include non steroidal anti-inflammatories, antibiotics, anticonvulsants, antidepressants and
oral contraceptives, which are systematically reported in monitoring surveys [20, 21] of the
aquatic environment. However, this corresponds to a generic assumption and the reality shows
that almost all substances (or their metabolites/degradation products) used in human thera‐
peutics can be virtually detected, mainly in sewage or even in receiving waters. It is also
noteworthy to observe that representatives of all these pharmacotherapeutic classes co-occur,
simultaneously, in the same sample or matrix. Despite co-occurring in extremely low amounts,
usually ranging from the ng to the µl per litre, it is not possible to discard the possibility of
exertion of effects, mediated or not by the same receptors activated during human therapy.
This poses important challenges, not only in analytical terms (which are out of the scope of
this chapter), but especially in terms of the toxicological deleterious outcomes resulting from
exposure to such complex mixtures, in individual terms (altered physiology of exposed
organisms) and to the ecosystem [22]. Given these main topics, the major scientific question
addressed here can be described as an interconnected two-tier approach: do pharmaceutical
drugs, or metabolites/residues, exert deleterious effects in wildlife? If so, what is the type of
effects to be expected, and what the extent to be considered? To answer these two issues, it
will be necessary to adopt new strategies to surpass the usual difficulties in obtaining responses
or measurable biological effects. Until the present day, few studies clearly showed the
relationship between realistic conditions of exposure and deleterious effects caused by
pharmaceuticals in non-target organisms. Considering the most frequently adopted toxico‐
logical endpoints (e.g. death, growth impairment) and the levels, concentrations or dosages
required to elicit such effects, it is possible to state that traditional approaches are not suited,
for most cases, to address the effects of drugs in aquatic organisms. Thus, it is mandatory to
select an additional set of tools that may address the issues initially raised, and constitute future
testing guidelines for pharmaceuticals in the wild. The combination of standardized methods,
well-established analytical techniques, and new biochemical strategies (including gene
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expression/epigenetics) might result in the establishment of a link between the low levels of
exposure and biological responses in non target, environmentally exposed biota.
2. Effects to be expected from drug exposure
It is impossible to predict the effects of drugs in the wild, given their sheer number and the
possible interactions among them in the wild. The mere quantity of different drugs in use in
modern human therapeutics is overwhelming, and prevents the establishment of any plausible
prediction in terms of toxicity of complex mixtures, such as urban effluents. The human use
of pharmaceutical drugs in the European Union is vast, and approximately 3000 distinct
substances are used, including substances from different pharmaco-therapeutic classes such
as anti-inflammatories, β-blockers, oral contraceptives, blood lipid regulators, antibiotics and
others [23]. This is a brief, albeit comprehensive summary of the therapeutic classes one can
find in the aquatic compartment, from an empirical perspective of only considering classes of
drugs that are used in extremely high amounts. However, this is a criterion that is not exempt
of drawbacks or criticisms, since the mentioned classes, those that are used and dispersed in
the highest amounts, are not necessarily representative of drugs with the highest biological or
toxicological activity. For instance, cytostatic or anticancer drugs are extremely active and
biologically aggressive, despite not being extensively used [24]; however, these substances are
among the most active environmental drugs [25]. It is thus extremely difficult to prioritise
substances only based on simple criteria of use and consumption; more difficult is the task to
develop and validate markers of toxicological interest to be used in routine analysis.
Furthermore, the presence of an even larger number of metabolites [26], and products of
degradation by natural or anthropogenic means (photodegradation, hydrolysis, microbial
degradation, chemical treatment processes at STPs, chemical reaction among drug residues
and with other substances) implies the need to include the possibility of toxicological interac‐
tions among all compounds that may be present in a given environmental (especially water)
sample; these interactions, that may result in increased toxicological activity, has been already
shown to be a possibility in the wild [27, 28]. It is not just a matter of selecting a biological
response, but to choose the one most likely to respond to this vast group of compounds, in a
specific organism that may be successfully analysed, both in field surveys and in laboratory-
based bioassays. It is not just feasible to study all pharmaceutical compounds, on all putative
model organisms.
3. Typology of toxic effects elicited by drugs and its relation with
pharmacology
The toxicity of pharmaceutical drugs in exposed aquatic biota is frequently determined by
their intrinsic pharmacology and toxicology, and outcomes that are already described for other
species are also possible to occur in aquatic organisms [29]. Additionally, other toxic effects
may not derive at all from the known pharmacology of these substances, and can indeed result
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from specific biochemical and physiological pathways that are over-stimulated in highly
responsive species. Thus, it is possible to expect a wide range of toxic effects, which difficult
the process of selection of adequate and responsive toxicological endpoints to be observed and
studied, both in monitoring and in laboratory based assays.
Despite the multiplicity of effects drugs can cause on non-target aquatic organisms, the
selection of a marker of toxicity is sometimes extremely difficult. It is impossible to select a
single biomarker that will be equally responsive to all drugs, considering the diversity of
pharmacological mechanisms involved in the activities of such a large number of substances.
Consequently, it must be emphasized that a thorough process of selection of adequate markers
of toxicity is mandatory. However, the quest for a putative toxic effect of a drug can be directly
connected to its mode of action, in pure pharmacological terms. This was the case of anticho‐
linesterasic compounds of therapeutic use, such as pyridostigmine and neostigmine, as shown
by Rocha et al. [30]. This study showed that the most likely effects of environmental contam‐
ination by these two substances could be related to cholinesterasic impairment, a key factor
encompassing other effects at the individual and population level, such as reduced feeding
behaviour and decrease offspring production. However, this study was not followed by other
successful attempts to establish relationships between drug exposure and potential ecotoxi‐
cological effects, and very scarce is the number of published papers that point this possibility.
The study conducted by Rodrigues et al. [15] evidenced that the same drug, pyridostigmine,
could elicit similar results in the fish species Lepomis gibbosus, in terms of cholinesterasic
inhibition; however, this pattern of response was not reflected by behavioural modifications,
despite the occurrence of neurotoxicity. Drugs can act by pathways that are also shared by
other classes of compounds, which share with drugs the same aquatic matrix. Cholinesterasic
inhibition was again the target of the study by Nunes et al. [31], when studying the combination
effects of a pharmaceutical drug, pyridostigmine, and two common environmental contami‐
nants (the metal copper, and the organophosphate pesticide chlorfenvinphos), well known for
their ability to impair cholinesterasic activity of exposed aquatic organisms. This study showed
that the combination of the three compounds, even for realistic levels, could result in a
toxicological outcome that constitutes the exacerbation of the pharmacological pathway
activated by the drug pyridostigmine.
The environmental effects of other substances of therapeutic use are also related with their
intrinsic effects. One of the most thoroughly characterized examples is the one of antibiotics.
By being discharged into the aquatic environment, often maintaining intact their pharmaco‐
logical properties, antibiotics still exert their effects on wild bacterial species [32]. This favours
the selection of resistant strains, by means of dispersing resistance genes among susceptible
bacteria. This phenomenon has been extensively characterized, and derives from the anthro‐
pogenic pressure exerted by human residues containing drugs that are released into the
environment, favouring the dispersion of ancient natural genes that encode resistance
mechanisms [33, 34]. To address the issue of antibiotic presence and effects in the environment,
namely those that can increase gene transfer among bacterial strains, a common strategy is to
analyse where these genes can be found, especially in the water compartment, which is the
most vulnerable to this issue. The review by Zhang et al. [35] summarizes the efforts recently
devoted to the development of new methodologies to characterize the dissemination of
resistance genes in the wild following antibiotic release from human activities. It is thus
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possible to conclude that the mere analysis of genes encoding resistance factors can be
considered an effective tool to analyse the effects of antibiotics in the wild.
Effects of other drugs can involve alterations in the regulation of the endocrine system. The
use of synthetic oral contraceptives, glucorticoids and others is one of the main causes for the
ubiquitous presence of these classes in most aquatic matrices, where they maintain their
biological effects [36]. Some of these compounds have already been demonstrated to exert
potential endocrine effects in exposed wildlife, even in the ranges of concentrations in which
they were found [37]. Despite their present levels of contamination, which are indisputably
low, the large use and liberation of these compounds into the aquatic compartment will not
exempt this endocrine disrupting substances from exerting deleterious effects on exposed
biota, as reviewed by Runnalls et al. [38]. In fact, the effects caused by this class of compounds
have already been documented, especially in terms of development, metamorphosis, and
sexual dimorphism, in amphibians [39], fish [40, 41], molluscs [42], and also crustaceans [43].
It is not surprising that these compounds, even after excretion, maintain their initial pharma‐
cological properties. However, effects elicited are well distinct from those caused in humans,
and can include feminization and significant alterations in individual features and population
structures, which constitutes a major effect in ecological terms. So, it is possible to conclude
that the assessment of endocrine disrupting effects is another valid example on how to use the
pharmacological properties of a given class of chemical drugs to search for their effects in the
environment. The study conducted by Velasco-Santamaría et al. [44] evidenced that the
presence of such compounds in the wild can also be potentiated by the concomitant presence
of other substances with similar pharmacological properties and therapeutic use. The synthetic
oestrogen ethinylestradiol can exert increased toxic endocrine effects in the presence of another
endocrine active pharmaceutical, such as trenbolone, in the marine fish species Zoarces
viviparous.
4. Mortality, growth impairment an other classic tools
Despite their traditional use for the toxicity assessment of a large number of substances,
mortality and growth impairment endpoints have been extensively used to describe the
toxicity of pharmaceutical substances towards wild biota. In fact, more than reflecting real
scenarios of contamination, the validity of calculating and interpreting mortality data relies
on the establishment of sublethal toxicity criteria and to analyse in comparative terms, the
ecotoxicity of substances that act by unknown (or largely uncharacterised) mechanisms of toxic
action. In fact, LC50 values of pharmaceutical drugs are well suited to establish rankings of
ecotoxicity among very distinct compounds, and these criteria are straightforward to imple‐
ment and interpret. However, these endpoints are not a first choice if one requires the
establishment of complex mechanisms, or even effects at extremely low levels, which are likely
to cause alterations other than death, immobilization, or impairment of the population growth.
These responses are not fine tuned alterations, and may be seen as blunt tools for toxicity
characterization, with poor of even null ecological relevance.
The number of ecotoxicity studies analysing lethality or growth impairment is thus consider‐
able. The study published by Carlsson et al. [45], showed that antiparasitic drugs could exert
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extreme toxicity, when compared to antibiotics, thus threatening the survival of zebrafish
embryos. The crustacean species Daphnia magna was very sensitive to the antidepressant
sertraline, as shown by Minagh et al. [46]; this compound was capable of inducing strong
alterations in the population of this crustacean species, after 21 days of exposure. Population
changes were also observed after chronically exposing D. magna to the compounds testosterone
and 4-hydroxyandrostenedione, even for ecologically relevant levels [47], reinforcing the
possibility of exertion of deleterious effects in the wild. Another crustacean, namely Neocaridina
denticulate, demonstrated to be extremely sensitive in terms of lethality to a combination of
pharmaceutical drugs (paracetamol and ibuprofen) commonly found in the aquatic environ‐
ment [48]. The ecotoxicological effects of mefenamic acid on D. magna and Moina macrocopa
were evaluated by Collard et al. [49]. This study showed that lethal effects were not likely to
occur for already reported levels of this compound; however, the chronic exposure to this
compound showed that changes in reproduction are possible, especially in the case of M.
macrocopa.
On the other hand, the absence of potential risk posed by the presence of clofibric acid was
evidenced by the study by Nunes et al. [50] and by Emblidge and DeLorenzo [51], in multi‐
species assessments that focused on mortality and growth impairment as toxicity endpoints.
Similarly, the work by Ferreira et al. [52] evidenced the absence of potential lethal effects posed
by antibiotics (oxytetracycline and florfenicol) on the crustacean species Artemia parthenogene‐
tica. Despite not exerting lethal effects, several combinations of pharmaceutical drugs (includ‐
ing an ecologically relevant mixture) were capable of causing significant alterations in
zebrafish embryos, as shown by Madureira et al. [53]. The antibiotic oxytetracycline was shown
to be reasonably safe towards the fish species Labeo rohita, since the lethal levels were well
above concentrations that are not likely to be found in the wild, as shown by Ambili et al. [54].
Growth of autothrophic organisms is another endpoint likely to respond to exposure to human
use drugs; the study conducted by Berninger et al. [55] showed the refractivity of the aquatic
plant species Lemna minor to the drug diphenhydramine. Somewhat similarly, the work
conducted by Nunes et al. [56] evidenced the occurrence of an oxidative-based response of
two species of the genus Lemna (L. minor and L. gibba) elicited by the drug paracetamol, which
resulted in significant growth alterations. On the other hand, the study conducted by Ferreira
et al. [52] presented evidences concerning the toxicity of the antibiotics oxytetracycline and
florfenicol on the microalgae species Tetraselmis chuii.
5. The quest for new biomarker tools: Oxidative stress
As seen before, the transformation of a pharmacological effect into a biomarker, can thus work
as a reliable indicator of exposure of wild organisms to several classes of pharmaceutical drugs.
Despite the presented evidences, describing successful cases in which the pharmacology of a
drug (or a group of drugs) may also be used to study its toxicity, the majority of therapeutic
drugs do not exert effects that can be interpreted as reliable environmental biomarkers. There
are two major drawbacks of this approach: the first reason is related with the levels in which
these substances are found, and the second most important, is the absence of a counterpart
response in wild organisms of the response elicited in human patients.
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Toxicity is a matter of dose, and can be generally described by a dose-response relationship.
Assuming that these compounds are found in extremely low levels, the exertion of a clear toxic
response (e.g. death, immobilization, impairment of reproduction) is not always possible. It is
thus important to know in detail the mechanisms by which the drugs not only exert their
pharmacological activities, but also those involved in adverse effects, metabolism and
detoxification processes, and other accessory or side-effects that the drugs may cause. Only by
means of knowing these fundaments of pharmacology and toxicology it is possible to select
biomarkers that will respond satisfactorily at extremely low levels of exposure. Given the
extremely low levels in which drugs are found in the aquatic compartment, effects are
sometimes minor and negligible, or may even be considered null or absent if an adequately
responsive biomarker is not employed. This can be a real challenge for ecotoxicologists, since
specific biomarkers, others than the main pharmacological effect, that signal a biological
alteration following an exposure to drugs in concentrations between the ng/l to µg/l are not
abundant.
On the other hand, drugs are designed to be safe for human patients, and it is possible to
suggest that this somewhat harmless nature can also prevent drugs from causing extreme
toxicity in other organisms. However, drugs can indeed cause multiple effects, which do not
occur by activation of specific single receptors, but reflect major changes in the homeostasis of
exposed organisms. The presence of pharmaceutical compounds can cause changes at many
different levels, including in the redox cycle of exposed organisms; these may cause the
formation of reactive chemical species, capable of inducing damages to biological structures.
Therefore, the quantification of oxidative stress biomarkers is important to evaluate the redox
status of the exposed organisms. Several studies have already shown that, even for realistic
levels of contamination, some compounds can exert pro-oxidative effects, measurable mostly
in terms of modification of the antioxidant defence mechanism of exposed aquatic organisms;
in many cases, membrane lipid peroxidation is a likely outcome of oxidative damage, and this
event can be also quantified [8, 13, 56, 57, 58, 59]. The exertion of oxidative stress is a factor to
consider when evaluating long term, thus realistic, exposures. Considering that exposure to
anthropogenic therapeutic drugs can occur during a significant portion of the entire life cycle
of a given organism, it is not possible to exclude the occurrence of cumulative processes ending
up in irreversible conditions. In fact, oxidative stress, if sustained for long period, can also be
the cause of genotoxicity. Data from the literature sustain the exertion of deleterious effects of
specific pharmaceutical compounds, including genotoxicity on fish [60], and in crustaceans
(e.g. D. magna) [61, 62]. Consequently, it is possible to use oxidative stress not only as an
indicator of exposure to a broad series of compounds, but also as a predictor of other subse‐
quent effects, that may derive from oxidative alterations and damages.
The extended knowledge concerning the metabolic pathways required for the bioactivation
or detoxification of therapeutic compounds can also function as a valid source of analytic tools
for the assessment of effects. The activation by over-expression of metabolic enzymes, involved
in the detoxification of pharmaceuticals, is a probable event whenever a biological system is
challenged by exposure to drugs in the wild. Among metabolic enzymes prone to over-
expression, one can identify mainly those involved in the direct metabolism of drugs. The
activities of phase I metabolic enzymes, for example (such as cytochrome P450), and phase II
metabolic reactions (namely isoenzymes glutathione-S-transferases, GSTs), can also be
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increased in aquatic organisms by exposure to pharmaceutical drugs [7, 8, 13]. Being routinely
quantified in modern ecotoxicological laboratories, the activities of such enzymes are intrins‐
ically interesting to quantify not only the level of exposure to drugs, but also the likely
consequences of drug exposure. This may be justified since these enzymatic forms are not only
involved in the bioactivation/detoxification of drugs, but do also participate in numerous
endogenous processes, which can be altered following an environmentally drug-induced
chemical insult. The broad spectrum of these analytical tools is also a factor to consider, being
highly unspecific, effects both phase I and II metabolic enzymes can indeed respond to a
multiplicity of therapeutic classes.
6. Alternative tools to assess the environmental effects of drugs: Toxicity,
pharmacology and other effects
Several toxicity assessment projects have relied in the development and validation of new tools
to quantify the extent of the toxic response. As previously stated, known pharmacological
properties can serve as a comprehensive source of biomarkers to be used in ecotoxicity
assessments. However, some of the responses of wild organisms to drugs may be based on
physiological mechanisms that are not directly related (activated or impaired) following
patterns included in the pharmacology of pharmaceutical substances. Some of these responses
are purely paradoxical, while others are only the reflex of the activation of mechanisms and
receptors in wild organisms that were never studied and/or identified in common experimen‐
tal models.
This is the case of behavioural alterations in several wild organisms. The work by Berninger
et al. [55] showed that the fish species Pimephales promelas was highly sensitive to the anti-
histaminic drug diphenhydramine in terms of feeding behaviour. The feeding behaviour was
also modulated after exposure of the fish Perca fluviatilis to the antidepressant sertraline, as
evidenced by Hedgespeth et al. [63]. Behaviour is also a trait that can be significantly changed
after exposure to pharmaceuticals, both in fish [64], and in crustacean species [65]. Strong
behavioural alterations were also reported by Nunes et al. [13] after the exposure of the fish
Gambusia holbrooki to the neuroactive compound diazepam, with impairment of the swimming
capability. An opposite pattern has been presented by crustacean species, which seem not to
be equally responsive to pharmaceutical drugs. As evidenced by Nieto et al [66], the food
ingestion behaviour of the freshwater crustacean Atyaephyra desmarestii was not affected by
ecologically relevant levels of several therapeutic drugs, such as diclofenac, ibuprofen, and
carbamazepine. Food ingestion was also affected following exposure of Xenopus laevis to
fluoxetine, as demonstrated by Conners et al. [67], thus conditioning the development of this
organism during its early life stages. Antidepressants that exert their therapeutic activity
through the selective inhibition of serotonin reuptake are likely to be adequate candidates to
alter the behaviour of a large number of aquatic organisms, considering that the most promi‐
nent pathway involved in their activity is highly conserved. According to the editorial by Ford
[68], specific compounds including sertraline and fluoxetine, can dramatically alter the feeding
behaviour profile of a large number of aquatic organisms, from fish to crustaceans.
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The endocrine disrupting effects of several human use drugs has been the subject of research
for several years, and quite a few studies report the occurrence of significant effects caused by
drugs (e.g. anti-inflammatories) on fish [69]. Endocrine disruptive effects caused by pharma‐
ceuticals are not exclusive to fish, since invertebrates, such as crustaceans, are also prone to be
affected in their endocrine functions by exposure to pharmaceutical drugs, as reviewed by
Hutchinson [70]. Neuroendocrine effects are another aspect of this issue. Considering that a
large number of pharmaceutical drugs act by altering the expression and effects of biological
compounds of high physiological importance (e.g. neuropeptides, neurotransmitters, or
neurohormones), it is with no surprise that similar mechanisms can be impaired in non-target
species environmentaly exposed to these same drugs. The consequences are not only so far
uncharacterised, but also, unpredictable. Consequences to be expected will naturally include
alterations in the physiology of exposed wildlife, affecting behavioural traits, or the hormonal
homeostasis, which are of fundamental importance to the organisms and to the ecosystem. It
is thus expectable to observe impairments at several levels, such as reproduction, develop‐
ment, growth, response to chemical aggression or other sources of stress [71, 72]. The neuro‐
endocrine effects of specific compounds, such as sertraline, were shown by Conners et al. [67]
in tadpoles of the species Xenopus laevis. This antidepressant substance caused significant
developmental impairments during the early life stages of this organism, which occurred for
ecologically relevant levels. Another antidepressant drug, such as fluoxetine, was also capable
of inducing strong alterations in the reproductive physiology of the fish species, Carassius
auratus. Another antidepressant, mianserin, was also related to estrogenic activity in fish (Danio
rerio) by inducing molecular biomarkers of estrogenicity (such as vitellogenin1 and zona
pellucida proteins), as evidenced by van der Ven et al. [73]. The study conducted by Mennigen
et al. [74]concluded that exposure to relevant levels of this substance could alter the expression
and release of several physiological hormones, thus compromising the sexual behaviour of
this fish species. Therapeutic drugs such as paracetamol and lincomycin are also involved in
endocrine disruption effects. The study conducted by Kim et al. [75] showed that these two
pharmaceuticals could affect the steroidogenic pathway and increase estrogenicity, in crusta‐
ceans (D. magna and Moina macrocopa), but also in fish (Oryzias latipes). These effects were
translated into a significant reduction in juvenile survival of fish, and on a significant increase
in the vitellogenin levels in male fish. Other substances, such as furosemide and several fibrates
(e.g. bezafibrate, fenofibrate and gemfibrozil) can also exert this type of endocrine effects.
According to the data obtained by Isidori et al. [76], these substances were shown to activate
the human estrogenic receptor α, thus favouring estrogenic responses in wild organisms.
Mefenamic acid is another example of an endocrine compound whose pharmacology in most
experimental organisms does not include this aspect. However, the data compiled by Collard
et al. [49] showed its involvement in endocrine effects in fish (D. rerio), evidenced by alterations
in vitellogenin and its mRNA expression, overexpression of genes of the hypothalamus–
pituitary–gonad axis, and histological changes in ovaries of exposed females.
Epigenetic effects can also derive from the environmentally-driven impact of specific com‐
pounds; exposure to persistent organic pollutants (including pharmaceuticals) or endocrine
disrupting chemicals are examples of classes of chemicals that have been related to alterations
in epigenetic marks, including in fish and cladocerans (Vandegehuchte and Janssen, 2011) [77].
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Several published papers refer that deleterious effects of transient chemical exposure (namely,
via environment) of D. magna can result in the transference to nonexposed generations through
epigenetic inheritance [78, 79, 80], which is a decisive factor to link ecotoxicological effects
observed at the levels of communities to alterations at the ecosystem levels [81]. The effects of
chemical pollutants on the epigenetics of fish is also significant, as shown by the screening of
pollution resistance of north American fish species [82]. Alteration of gene expression is also
another factor to consider after environmental exposure to chemical stressors; several papers
show the responsiveness of aquatic organisms to environmental pharmaceuticals, demon‐
strating the validity of this approach [83, 84].
Specific drugs, not anticholinesterasic by nature, can also impair neurotransmission, by
cholinesterasic inhibition [85]. One of the most significant examples is the one represented by
zinc pyrithione. According to the work developed by Sánchez-Bayoa and Goka [86], this anti-
dandruff compound is extremely toxic to several aquatic organisms, including the crustacean
D. magna. Despite being photodegradable, recent studies show that zinc pyrithione may exert
important toxic effects on aquatic organisms (e.g. Paracentrotus lividus and Mytilus edulis), even
at extremely low levels [87]. Effects of zinc pyrithione are not restricted to invertebrates, since
fish species are also extremely sensitive to the presence of this compound [88]. The products
of degradation of zinc pyrithione can be of great environmental concern per se, since the effects
of such compounds on several marine organisms are well known. The toxicity of zinc pyri‐
thione has been documented for organisms such as the algae species Skeletonema costatum, the
crustacean Tigriopus japonicus, and the fish Pagrus major [89]. The mechanism of toxic action of
zinc pyrithione metabolites includes AChE inhibition, as shown by Mochida et al. [90].
The energy metabolism of wild organisms is a putative target for pharmaceutical toxicity. As
shown by Mennigen et al. [91], exposure to the drug fluoxetine could result in significant
alterations in the fish species Carassius auratus, namely in terms of energy metabolism. Low
levels of exposure were causative of anorectic effects, while higher levels could directly
compromise the hepatic glucose metabolism, by means of depressing the activity of the
gluconeogenic enzyme fructose-1,6-bisphosphatase. Chronic exposure of marine mussels
(Mytilus sp.) to two therapeutic drugs, genfibrozil and diclofenac, showed the interference of
these substances on several parameters, including energy metabolism features [92]. The
respiratory activity of exposed organisms is another function that can be altered after exposure
to anthropogenic compounds, which interfere with metabolic pathways used by organisms to
obtain energy (anaerobiosis vs. aerobiosis) [7]. This study evidenced the roles of both clofibrate
and clofibric acid, hypolipidemic fibrates used in human therapeutics, in the increase in muscle
lactate dehydrogenase activity, thus favouring the less energetically efficient anaerobiotic
pathway.
7. Future directions: A combination of tools
From the previous sections, it was made clear that it is extremely difficult to search and define
without any shadow of doubt the biological effects to be expected from a large number of
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extremely different chemical substances, exerted on a vast multiplicity of organisms. Not only
are the substances very different per se, thus exerting distinct effects, but also the organisms
can have alternative pathways and receptors that make them more or less prone to the exertion
of those same effects. It is not possible always to rely on the well-described human pharma‐
cology, despite the large number of studies that sustain the most common effects, since humans
are not environmentally exposed to the majority of these substances or to their residues.
However, some of the effects are shared both by humans and by other organisms in the wild,
a decisive factor when one tries to select an adequate tool to quantify an effect elicited by a
pharmaceutical drug in the environment.
The present scenario shows us that we are halfway between the total lack of data concerning
pharmaceutical effects in the wild, and a full and comprehensive knowledge about their faith
and ultimate consequences. A large effort has been undertaken and toxicity of several
pharmaceutical classes is nowadays already characterized in a vast number of organisms.
Despite the validity of this effort, other pharmaceutical classes are not fully understood in their
interaction with biota, thus requiring the development of additional attempts until a definite
light is shed on this issue. Presently, environmental scientists dealing with this issue still have
to face a significant array of drawbacks, from the simple lack of data for some drugs/organisms,
unpredictability of data and, of the biological responses in somewhat exotic species, con‐
founding factors that already occur for other studies, but whose influence is exponentially
increased in this specific area, lack of analytical tools, such as biomarkers with enough
sensitivity to face the extremely low levels found in the wild and that are able to understand
highly subtle biological responses, lack of test protocols or species well adapted to be used in
ecotoxicological testing under conditions of brackish water, tropical or artic climates, or
extreme environments, in which drugs are also likely to occur.
Despite not being the core of this chapter, the quantification of the levels of pharmaceutical
drugs in the wild, especially in the aquatic environment, is crucial. It is important to know in
detail the compounds that may exist (or co-exist) in the same matrix, since these compounds
are important to select an analytical tool/biomarker that will allow the prediction of biological
effects. It is also of fundamental importance to know which are the most representative
compounds (or pharmacotherapeutic classes) in a given sample also to establish causal
relationships between their levels and the extent of the observed biological response. Only
with a complimentary approach comprising hydrology, water analytical chemistry and
biological assessment of effects it will be possible to fully characterize the impact of drugs on
the wildlife.
The typology of exposure is also a matter of concern. From the previously mentioned studies,
two main types of exposure were adopted in the majority of studies: acute (short-term) and
chronic (long term). The use of short-term exposure periods is somewhat neglected, but this
is not a totally invalid strategy. Despite not having the relevance of a long period of exposure,
which reflects the most likely conditions of exposure in the wild, short exposure periods are
also of extreme importance, and must be included in bioassays for the assessment of the effects
of pharmaceutical drug. Acute assays are important since they allow researchers to test the
responsiveness of a specific test species towards a given drugs, Acute exposure can also be of
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importance to define rankings of comparative toxicity for several substances, independently
from their mode of action and toxicity. Data from acute tests can also be useful to determine
ranges of concentrations representing sublethal levels to which organisms may be exposed.
Finally, the entire set of information potentially gathered from this type of test may serve to
prioritise compounds to be studied under chronic conditions of exposure. However, and if one
considers the need to increase the ecological relevance of data obtained from ecotoxicity tests,
chronic assays are likely to represent a more credible simulation of what happens in the wild.
Organisms are frequently subjected to contamination during considerable periods of their
entire life cycle, or may even contact with chemical pollution of anthropogenic origin for
different generations. It is thus important to prioritise a testing strategy that simulates these
conditions, and the most adopted type of bioassay, despite its inherent difficulties, is the
chronic exposure. Chronic exposures can more easily mimic real events, occurring under
realistic low levels of contaminants, and can consequently increase the ecological relevance of
the obtained data. Furthermore, the selection of chronic exposures can permit the proposal of
multispecies assessments (e.g. mesocosms), which are obviously advantageous if one intends
to simulate real environmental conditions. On the other hand, multispecies assessments are a
valid approach, since the sensitivity of distinct organisms towards pharmaceuticals is fre‐
quently very diverse.
From the majority of the cited studies, it is possible to conclude that a biomarker-based
approach is valid to obtain information regarding specific pathways involved in the toxic
response. This does not necessarily imply that more traditional approaches (including
mortality, or growth/population effects) are fully inadequate to assess the ecotoxicological
effects of drugs. Nevertheless, the low levels of exposure make difficult the exertion of such
effects, and the resultant toxicity often occurs by impairment of specific, subtler, biochemical
pathways. It is thus important to analyse the sub-individual level, and more biomarkers must
be proposed and fully validated. Effects at the molecular level, including enzymes, must be
interpreted as signalling tools for effect or damage in biological systems. Given their overall
importance, specific pathways must be primary sources of analytical tools. It is possible to
suggest that novel biomarkers can derive from analysis of the enzymatic machinery involved
in the energetic metabolism, gene expression and epigenetics, and damage (e.g. of oxidative
nature) repair. These will be the most likely biomarkers of contamination of the future.
The next step will be transposing laboratory biomarker-based assays, with a combination of
chronic-acute exposure of multiple species to other alternative models, namely under field
conditions. It is now mandatory to propose new test species, well adapted to conditions that
do not represent standard settings: species from tropical/polar (or otherwise extreme) regions
must be analysed following the above-described strategy, and their use for ecotoxicological
purposes validated. This will be of crucial importance to transfer bioassays from the laboratory
to the field, increasing the validity of data and of the conclusions drawn.
Finally, a last step will combine the simultaneous analysis of complex mixtures of drugs.
Frequently, environmental matrices are contaminated by a large number of distinct pharma‐
ceuticals; any analytical procedure based on the quantification of effects caused by a single
chemical will always be unsatisfactory, and will underestimate the actual toxicity of complex
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but realistic mixtures. To avoid this underestimation, it will be of the uttermost importance to
know the general interaction profiles that may occur for a large number of test species, caused
not by isolated single compounds, but by the main representatives of known therapeutic
classes: not being possible to test the potential interactions occurring by the simultaneous
presence of hundreds or even thousands of compounds in the same matrix, a more systematic
approach may involve the definition and characterization of putative biological relations of
pharmacotherapeutic classes among each other.
8. The effects of drugs in the wild
Despite the considerable number of cited research articles so far, the present chapter would
not be satisfactorily summarized without a critical evaluation of the potential ecological
damages posed by pharmaceutical residues. The major drawbacks for the analysis of effects
caused by pharmaceuticals are also the most important defence against their risks: their
extremely low levels. Being present in residual amounts, sometimes below the ng/l range, the
majority of drugs do not attain levels capable of exerting effects. However, the simultaneous
presence of compounds that act via a similar pathway may favour the exertion of effects. Still,
few are the examples of substances for which this behaviour has been described. Despite the
lack of reported effects, and the impossibility so far of establishing a direct, unequivocal
relationship between pharmaceutical exposure and deleterious effects in wildlife, an increas‐
ing number of studies has brought the issue of ecological relevance of data to the discussion.
By testing already reported levels of contaminants, some researchers have already claimed
having demonstrated the putative effects of drugs in exposed organisms that are also likely to
occur in the wild. This has been the case of several fibrates [7], synthetic hormones [93],
ivermectin [94], paracetamol [1, 57, 59], ibuprofen [95], neostigmine and pyridostigmine [15,
30, 31], fluoxetine and other antidepressants [93, 96]. However, the majority of studies
published so far do not demonstrate this intrinsic association between pharmaceuticals
contamination and deleterious effects. Nevertheless, research studies on this matter have
clearly demonstrated the responsiveness of a large number of species towards drugs, evi‐
dencing the potential for toxic effects if a threshold level is attained and surpassed. This is of
the uttermost importance, since it clearly shows that some of the highly conserved pathways
used and activated by pharmaceutical drugs in humans, are also present in a significant
number of wild organisms; this increases the possibility of biological-chemical interaction,
with sometimes totally unpredicted overall effects. The protection created against the effects
of human drugs by their low levels can thus be simply temporary, considering the ever-
increasing amount of drugs and their residues in the wild.
9. Conclusions
The need to understand the potential effects of a large number of biologically active substances
in the wild, has driven researchers to the development of new assessment methodologies.
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Unlike other substances with human origin, pharmaceutical drugs are active, and may pose
significant risks even after their elimination and for long periods. Being excreted in extremely
high amounts and on a daily basis, such substances are pseudopersistent and recalcitrant. Not
even the implementation of dedicated sewage treatment systems endured to reduce the global
amounts of drugs entering especially the aquatic environment. Consequently, the presence of
such substances is now a global reality, needing to be dully characterized. Non-target species
are the most likely and vulnerable targets for the exertion of deleterious effects. The study of
putative toxic effects requires the development, implementation and validation of novel
analytic tools, specifically devoted to the particularities of drug contamination. From the
revised literature, it is possible to anticipate that ecotoxicological analysis, in the future, will
require the combination of distinct tools, on a complementary basis. The tools to be used in
the future will not only respond to extremely low levels of contamination, but will include
signalling responses well suited to diagnose exposure to specific classes of drugs. Despite not
being entirely adapted to the issue of contamination by low levels of pharmaceutical drugs,
standardized bioassays can be a valuable tool, if complemented with adequate molecular and
subindividual endpoints. Being impossible to characterize the entire set of toxic responses
elicited by single, individual compounds, it will be important to know the most important
toxic responses of common pharmacotherapeutic classes, to allow the prediction of potential
interactions. The use of multispecies assessments will also be important, since the sensitivity
towards specific compounds is not necessarily comparable among distinct test organisms.
Long-term studies, favouring phenomena of bioaccumulation during important periods of the
organisms’ life cycles will allow knowing in detail the potential endocrine effects elicited by
specific compounds. Behaviour is another feature likely to be altered after pharmaceuticals
exposure, thus requiring the development of new testing methodologies to address this issue.
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